2 results
Approved WMOWill not start
2.1 Primary objectiveTo assess the rate of no progression (NPR) at 8 weeks following treatment with the combination of gefitinib and fulvestrant in EGFR mutated patients who failed previous treatment with reversible EGFR TKI*s (gefitinib or…
Approved WMOCompleted
The purpose of the study is to investigate how quickly and to what extent flurbiprofen is absorbed and eliminated from the body (this is called pharmacokinetics) when it is administered via a FTS. Furthermore, the pharmacokinetics of FTS will be…